ArticleFrontiers in pharmacology2026
Expert assessment of the attributes of high-cost medications: a case study of CAR T-cell therapy in the gulf cooperation council.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The influx of high-cost advanced therapies, particularly CAR T-cell therapies, poses profound economic and operational challenges for healthcare systems in the Gulf Cooperation Council (GCC). As the region transitions from volume-based procurement to Value-Based Healthcare (VBHC), decision-makers must balance the urgent need for innovative curative treatments with fiscal sustainability and limited local health economics data. Methods: This study utilized a quantitative expert preference rating approach, using a rating-based Conjoint Analysis to assess the utility and relative importance of key value drivers for CAR T-cell therapies. Eighteen Key Opinion Leaders (KOLs) evaluated four hypothetical CAR T-cell product profiles. Individual ratings for sequentially presented attributes were collected from participants and subsequently analyzed using an ordinary least squares (OLS) transformation regression model based on Multi-Attribute Utility Theory (MAUT) to estimate part-worth utilities. Results: The analysis identified labeled indications and outcome-based agreements as the dominant drivers of decision-making utility, with markedly higher estimated utility values than upfront price and individual efficacy or safety metrics. Specifically, a cohort-level Outcome-Based Agreements model, where reimbursement is conditional on the response rate of a treated patient population, generated the single highest utility value (U = 24.07). In terms of structural attributes, experts demonstrated a statistically significant preference for comprehensive Patient Support Programs (PSPs) and Technology Transfer commitments (local manufacturing) over simple scientific guidance or basic discounts. Conclusion: Decision-makers in the GCC prioritize risk-sharing mechanisms and broad therapeutic indications over traditional cost-containment strategies when evaluating high-cost CAR T-cell therapies. These findings suggest that to ensure equitable and sustainable patient access, policymakers must establish unified regulatory frameworks that facilitate performance-linked reimbursement models and incentivize the localization of advanced therapy infrastructure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.